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Abstract
Aims—The cardiovascular system is an important target of estrogenic compounds. Considering
the recent studies that question previously reported cardio-protective effects of estrogen, there is a
growing concern that estrogenic environmental compounds may contribute to the pathology of
vascular lesion formation.
Main methods—Real-time quantitative PCR was used to monitor the expression of genes
involved in vascularization. Using Bayesian network modeling, we determined a gene network
that estrogenic chemicals modulate in human vascular endothelial cells.
Key findings—We showed that planar and co-planar polychlorinated biphenyls (PCBs) induce
the expression of different genes compared to estradiol. Non-planar PCB congener 153 induced
NOTCH3 which is a new finding as well as CCL2 and IL8 similar to what has been reported by
other non-planar PCBs in endothelial cells. Our gene network indicated that experimental
treatments signal a network containing TGF-β receptor and NOTCH3; molecules biologically
relevant to signaling pulmonary vascular lesions.
Significance—We report in the present study that exposure of vascular endothelial cells to
environmentally relevant concentrations of estrogenic PCBs induce gene networks implicated in
the process of inflammation and adhesion. Our data suggest that PCBs can promote vascular
lesion formation by activating gene networks involved in endothelial cell adhesion, cell growth,
and pro-inflammatory molecules which were different from natural estrogen. Since inflammation
and adhesion are a hallmark in the pathology of endothelial cell dysfunction, reconstructing gene
networks provide insight into the potential mechanisms that may contribute to the vascular risks
associated with estrogenic environmental chemicals.
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Introduction
The cardiovascular system is an important target of estrogenic compounds through genomic
and non-genomic pathways (Chambliss et al., 2002). The estrogen receptor (ERα/β) has
been shown in human coronary arteries, endothelial cells, and cardiomyocytes (Kim-Schulze
et al., 1996;Yang et al., 2004). Recent studies question previously reported beneficial effects
of estrogen on the cardiovascular system. The Women's Health Initiative, indicated that
long-term use of estrogen did not decrease, and may have increased, the risk of
cardiovascular disease (CVD) (Rossouw, 2005). However, the use of estrogens to prevent
CVD has never been without controversy. For instance, The Coronary Drug Project was
discontinued because of a significant increase of coronary heart disease among men
receiving estrogens (1970;1973). Estrogen therapy in diabetic women was shown to be
associated with a worsening of coronary atherosclerosis and exacerbation of inflammatory
markers (Howard et al., 2004). And the use of the synthetic estrogen diethylstilbestrol to
treat prostate cancer was associated with increased cardiovascular morbidity and mortality in
men (Cox and Crawford, 1995).
Pulmonary arterial hypertension (PAH) is roughly twice as common in women compared to
men (Newman et al., 2004); whether this occurrence may be attributed to the hormone
estrogen is not clear. In the United States, PAH afflicts approximately 100,000 individuals
and is the cause of death in 20,000 people each year (Hyduk et al., 2005). Evidence suggests
that intra-luminal proliferation of endothelial cells causes PAH. Vascular lesions of severe
PAH consist of actively proliferating endothelial cells (Sakao et al., 2009). Since estrogen is
a known mitogen of endothelial cells, we postulate that pulmonary vascular lesions are a
consequence of excess or unopposed estrogen. Although beneficial effects of estrogen on the
endothelium have been reported (Cid et al., 2002); differences between endothelial cell
types could account for greater susceptibility of pulmonary arteries to estrogen-induced
inflammation and vascular lesion formation. Widespread contaminants in the environment
such as arsenic, tobacco smoke, and polychlorinated biphenyls (PCBs) have been reported to
possess estrogenic activity (Davey et al., 2007;Meek and Finch, 1999;Bitman and Cecil,
1970;Tavolari et al., 2006). Since the effect of estrogens on pulmonary vasculature is not
well studied, research elucidating the role of these compounds in the development of
pulmonary vascular lesions is highly relevant to cardiovascular public health.
Although estrogen-induced gene expression has been well studied in endothelial cells, there
is a lack of knowledge about how the expression profile differs from estrogenic
environmental chemicals. Several epidemiological studies have shown a link between PCB
exposure and increased risk of CVD (Gustavsson and Hogstedt, 1997;Hay and Tarrel,
1997;Goncharov et al., 2008;Tokunaga and Kataoka, 2003;Sergeev and Carpenter, 2005).
Considering the recent studies that question the previously reported cardio-protective effects
of estrogens, there is a growing concern that estrogenic PCBs may increase the risk for PAH
by inducing the formation of pulmonary vascular lesions. The present study aims to
investigate the differential effects of estrogens on candidate genes involved in
vascularization in human vascular endothelial cells exposed to environmentally relevant
concentrations (ppb) of PCB126, PCB153, and physiological concentrations of 17β-
estradiol.
Materials and Methods
Cell Culture
A telomerase-immortalized human microvascular endothelium (TIME) cell line was
obtained from American Type Culture Collection (Manassas, VA) to be referred throughout
this study as HMVEC. These endothelial cells have retained many of the phenotypic
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characteristics of the primary endothelial cells from which they were derived including
normal cell morphology and the capacity to form tubules in vitro (Venetsanakos et al.,
2002). Cells were grown in Endothelial Cell Basal Medium-2 (EBM-2) supplemented with
EGM 2-MV Single-Quots from Lonza (Walkersville, MD). Estrogen treatments were
studied under the following culture conditions: 75–80% confluent cultures were washed and
serum starved in phenol red-free medium for 3h. Thereafter, the cells were treated with
either PCB126, PCB153, or 17β-estradiol in phenol red-free medium supplemented with
10% charcoal/dextran-treated fetal bovine serum to avoid any estrogenic activity and
maintained for 24 hours.
Estrogenic chemical treatments
Stock solutions of PCB126, PCB153, and 17β-estradiol were prepared in dimethyl sulfoxide
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added to
control cultures. The level of DMSO in experimental media was less than 0.1%. PCB blood
levels have been reported to reach approximately 1000ng/ml (~3 M) in occupationally
exposed individuals (Wassermann et al., 1979). Our unpublished data showed a significant
increase in PCB-induced vascularization with PCB153 concentrations of 10–100ng/ml.
Based on known PCB blood levels from occupational exposure and our preliminary results;
we chose a 10-fold lower PCB dose of 100ng/ml (~0.3μM) to expose endothelial cells. Our
previous studies also showed endothelial cell proliferation and vascular tube formation at
physiological doses of 17β-estradiol (Felty, 2006;Felty and Porther, 2008); therefore
HMVEC were exposed to estradiol at 1ng/ml (~3.6nM). PCB congeners 2,2′,4,4′,5,5′-
hexachlorobiphenyl (PCB153) and 3,3',4,4',5-pentachlorobiphenyl (PCB126) were
purchased from AccuStandard (New Haven, CT) and dissolved in dimethyl sulfoxide
(DMSO). All other chemicals and reagents were purchased from Sigma (St. Louis, MO).
Real-time RT PCR
Total RNA was isolated and purified using the RNeasy Mini Kit from Qiagen (Valencia,
CA). RNA sample quality was verified by electrophoresis on a denaturing agarose gel and
then reverse transcribed into cDNA using the RT2 First Strand Kit from SuperArray
Bioscience Corporation (Frederick, MD) according to the manufacturer's protocol. The PCR
reactions using cDNA were performed in a Applied Biosystems 7300 Real-Time PCR
System using RT2 SYBR Green/ROX qPCR Master Mix and the manufacturer's thermal
cycler protocol (95°C for 10 min, followed by 40 cycles at 95°C for 15s, 60°C for 1 min).
The threshold cycle (CT) from each well was determined using ABI 7300 SDS software.
PCR array
PCR array analysis of cDNA from RNA isolated from HMVEC treated with vehicle control
(0.1% DMSO), PCB126, PCB153, or 17β-estradiol for 24h was performed in triplicate using
RT2 Profiler PCR array for Human Angiogenesis from SABiosciences, in accordance with
the manufacturer's instructions. PCR arrays were used to compare the relative expression of
84 genes for each array. Relative changes in gene expression between the treated and
untreated HMVEC RNA were calculated by the ΔΔCT method as previously described
(Livak and Schmittgen, 2001). First, target genes in each array were normalized to the
endogenous control or housekeeping genes: RPL13A, GAPDH, or ACTB. Next, each
treatment group was normalized to the untreated group (vehicle control, 0.1% DMSO).
Using the SABiosciences PCR Array Data Analysis Web Portal, fold changes in gene
expression were analyzed between groups using the equation 2−ΔΔCT, where ΔΔCT=
[CTtarget gene−Avg. CThousekeeping genes]treated group−[CTtarget gene−Avg.
CThousekeeping genes]control group. Each value is a repeat of three independent experiments.
ANOVA and Fisher's least significant difference test were used for multi-group
comparisons, with a P value of less than 0.05 considered significant.
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Gene Network Analysis
Given the emergence of datasets in medicine and biology with large number of variables,
Bayesian Networks have been successful in developing efficient algorithms that scale up to
datasets involving hundreds of variables in learning high quality predictive models from
genomic data (Yoo and Cooper, 2004). A Bayesian Network is a directed acyclic graph in
which each node represents a variable and each arc represents probabilistic influence. In
Bayesian Networks, each arc is interpreted as a direct influence between a parent node
(variable) and a child node, relative to the other nodes in the network.
Results
Although estradiol–induced gene expression in endothelial cells has been well studied, the
question of whether estrogenic PCB-induced gene expression differs from the natural
hormone 17β-estradiol has not been tested until now. Our previous studies have shown that
physiological concentrations of estradiol induce the formation of reactive oxygen species
(ROS) involved in signaling cell proliferation and vascularization (Felty, 2006;Felty and
Porther, 2008). To further study this phenotype, we used a PCR array to compare 17β-
estradiol to PCB-induced endothelial cell gene expression. We chose PCB153 because it
was shown to bind the ERα and induce vessel formation in endothelial cells (Tavolari,
Bucci, Tomasi, and Guarnieri, 2006). We chose a coplanar PCB (PCB126) to compare with
the non-coplanar PCB153; in order to determine whether the gene expression profiles
between these two PCB congeners were specific. Using the RT2 Profiler PCR array for
Human Angiogenesis, we have monitored the mRNA levels of 84 different genes involved
in vascularization. This array was selected because we previously reported estrogen-induced
redox sensitive signaling in vascular tube formation. Human endothelial cells were treated
with vehicle control (0.1% DMSO), 17β-estradiol, or PCB congeners 126 and 153 for 24h.
Fig. 1 depicts a log transformation plot indicating the relative expression level of each gene.
The red lines indicate a 3-fold change in gene expression compared to control. In Fig. 1A,
PCB153 treatment increased the expression of six of the 84 genes by more than 3-fold.
Expression of two genes, CCL2 and IL-8, was corroborated by other studies that reported
the same genes to be induced by non-coplanar PCB congener 104 in endothelial cells (Choi
et al., 2003;Eum et al., 2004). In Fig. 1B, PCB126 did not show a 3-fold increase in any of
the genes studied, instead approximately 90% of the genes were less than or equal to the
control. In Fig. 1C, estradiol treatment also did not show a 3-fold increase in gene
expression and followed a trend similar to PCB126 treatment. Hierarchical clusters were
used to analyze these expression profiles from the different treatments (Fig. 2). The
hierarchical clustering method performs a cluster analysis using a set of dissimilarities for
the gene profiles being clustered. Initially, each object is assigned to its own cluster and then
the algorithm proceeds iteratively, at each stage joining the two most similar clusters,
continuing until there is just a single cluster. At each stage distances between clusters are
recomputed by the Lance-Williams dissimilarity update formula according to the particular
clustering method being used. Among the treatment groups, we identified 5 clusters. The
largest cluster consisted mainly of genes related to growth factors and proteases. While the
second largest cluster showed a majority of cytokines and chemokines.
Genes regulated by estrogen treatments were organized by function to better understand
their profile (Table 1). The manufacturer's categories: Adhesion Molecules, Cytokines &
Chemokines, Growth Factors & Receptors, Proteases, Inhibitors, & Matrix Proteins, and
Transcription Factors; were used to organize the genes by function. In Table 1, genes that
exhibit at least a 2-fold regulation in expression in the estradiol, PCB126, and PCB153
treatments are highlighted in red if up-regulated and green if down-regulated. This
classification showed that PCB153 up-regulated significantly greater number of genes when
compared to estradiol. These genes included adhesion molecules CDH5, ITGAV; cytokines
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and chemokines IL8, IL6, CCL2, CXCL10; growth factors and receptors S1PR1, PDGFA,
TEK, TGFB2, VEGFA, VEGFC; and from the remaining categories ANGPTL4 and
NOTCH4. Endothelial cells depend on processes of migration, adhesion, and proliferation
when forming vessels. PCB153 significantly up-regulated: growth factors, adhesion
molecules, and pro-inflammatory factors relevant to the process of vascularization. When
we compared the coplanar PCB congener 126 to PCB153 we observed a significantly
different profile. PCB126 down-regulated many genes that were similar to PCB153;
however, PCB126 exposed endothelial cells showed more cytokines and chemokines
significantly down-regulated compared to both PCB153 and estradiol treated cells. In the
estradiol treatment; TGFB2 up-regulation was similar to PCB153 treatment. The majority of
down-regulated genes in the estradiol treatment were common to both PCB congeners.
We have applied Bayesian Networks learning method to further understand interactions
among the genes that respond to the treatments. Bayesian Networks is a knowledge
representation formalism that has been widely used in translational biomedical research for
constructing statistical graphical models and for generating causal hypotheses from data
(Yoo and Cooper, 2004). Since we wanted to identify interactions among genes that respond
to the treatments, we have categorized each gene's expression level to low (if the expression
level is one standard deviation lower than the mean expression level), no change, and high
(if the expression level is one standard deviation higher than the mean expression level),
based on the normalized expression level of all the genes in control and treatments. To learn
Bayesian networks among the genes, we then used a computer software called Banjo. Figure
3 illustrates the structure of a hypothetical Bayesian Network structure that contains five
nodes. The probabilities associated with this network structure are not shown. The network
structure in Fig. 3 indicates, for example, that Gene1 can regulate (influence) the expression
level of Gene3, which in turn can regulate the expression level of Gene5. The Markov
condition gives the conditional independence relationships that are specified by a Bayesian
Network: A node is independent of its non–descendants (e.g., non–effects) i.e., given its its
parents (i.e., its direct influences). Categorizing each gene's expression level to low, no
change, and high, based on the normalized expression level of all the genes in control and
treatments, we have identified the following genes that show identical expression pattern
based on the categorization of the genes (Table 2). Bayesian network inference with Java
objects (Banjo) software was used to analyze PCR array data of the estrogen treatments.
Bayesian gene networks were reconstructed using the expression profile of all 84 genes from
the RT2 Profiler PCR Array for Human Angiogenesis. Figure 3 shows the best Bayesian
network reported by Banjo. The node labeled “Experiment” in the figure represents the
experiment performed, i.e. Control, estradiol, PCB126, or PCB153. Other than the
Experiment node, each node either represents a group of genes previously mentioned or a
single gene. The lines between the genes denote inferred interactions. A continuous line
means a direct relationship between the two genes, whereas a discontinuous line indicates an
indirect association. The most significant network regulated by experimental treatments
revealed 31 significant genes. The network identified that the following genes to have direct
influence of the Experiment node, i.e., the following genes are the Markov Blanket
of“Experiment” node: G1, VEGFA, CXCL6, HPSE, and TGFBR1.
Discussion
Clinically, PAH causes an increase in pulmonary arterial pressure that leads to right
ventricular failure and death. Pulmonary hypertension has been reported to be associated
with the use of oral contraceptives (Kleiger et al., 1976). Estrogens found in oral
contraceptives are known to produce an increased incidence of pulmonary embolism
(Ramos K.S., Jr., 1996); however, evidence suggests that intra-luminal proliferation of
endothelial cells rather than pulmonary embolism causes PAH. Since estrogen is a known
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mitogen of endothelial cells, we postulate that pulmonary vascular lesions are a consequence
of excess or unopposed estrogen. In support of this concept, clinical cases of pulmonary
intimal vascular lesions have been associated with the use of oral contraceptives (Irey and
Norris, 1973).
In this study, we examined whether exposure of human vascular endothelial cells to
environmentally relevant concentrations (100ppb) of estrogenic compounds PCB153 and
PCB126 differed from the natural hormone 17β-estradiol with respect to effects on genes
involved in vascularization. Our findings show considerably different responses of
estrogenic PCB153 compared to estradiol treated endothelial cells. We have identified an
increase in the expression of adhesion molecules cadherin 5 and integrin α5; cytokines and
chemokines IL8, IL6, CCL2, CXCL10; growth factors and receptors such as TGFB2,
VEGFA, VEGFC; and NOTCH4 in endothelial cells exposed to PCB153. Interestingly,
PCB126 exposed endothelial cells showed a down-regulation of cytokines and chemokines
compared to both PCB153 and estradiol treatments. TGFB2 was the only up-regulated gene
that was shared between PCB153 and estradiol. PCB153 has been shown to induce
vascularization and inflammation in human vascular endothelial cells. A functional change
in CVD such as atherosclerosis is the activation of the endothelium that is initiated by an
increase in the expression of specific cytokines and adhesion molecules. Since endothelial
cell adhesion depends on molecules such as integrin α5 and cadherin, the gene network we
reported to be stimulated by PCBs may explain the mechanism through which estrogenic
chemicals can promote the development of vascular lesions.
Our gene network indicated that the estrogenic treatments may signal a network containing
TGFBR2, IL6, IL8, and growth factors such as VEGFA, PDGFA, and FGF2. Based on
previous studies, our results may be biologically relevant to signaling pulmonary vascular
lesions. For instance, inherited susceptibility to PAH occurs in families with mutations in
genes of the TGF-beta family of receptors (Davies and Morrell, 2008). Levels of growth
factors and IL6 in the pulmonary circulation of patients with PAH have been implicated in
vascular remodeling (Selimovic et al., 2009). Our gene network also showed a connection to
the NOTCH homolog 4 (Drosophila) also known as NOTCH3. A recent study reported
NOTCH3 signaling promotes the development of pulmonary arterial hypertension (Li et al.,
2009). Human pulmonary hypertension was characterized by overexpression of NOTCH3 in
small pulmonary arteries; furthermore the severity of PAH in humans and rodents correlated
with the amount of NOTCH3 protein in the lung.
Our data suggest that PCBs can promote vascular lesion formation by activating gene
networks involved in endothelial cell adhesion and inflammatory response which were
different from natural estrogen. Previous studies have reported anti-inflammatory effects of
estradiol on the endothelium. Vascular endothelial cells exposed to estrogen at
pharmacological doses decreased cytokine-induced adhesion molecule expression (Caulin-
Glaser et al., 1996). Our findings that show estrogen-induced expression of inflammatory
and adhesion molecules is consistent with what others have reported in the literature. For
example, at physiological doses (1–2ng/ml); estradiol was reported to increase β1, α5 and α6
integrin mRNA in subconfluent endothelial cells (Cid et al., 1999). Furthermore, estrogen
was shown to amplify the expression of adhesion molecules in cytokine stimulated
endothelial cells (Cid et al., 1994). These dual effects of estrogen may depend on the dose
and time of exposure.
ER-mediated signaling pathways are considered to support cell proliferation; however,
discrepancies between the binding affinity of various estrogens to the ER and their growth
potency both in vitro and in vivo have been reported (DuMond, Jr. et al., 2001;Bocchinfuso
et al., 1999). Although selective ER modulators (SERMS) such as tamoxifen and
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antiestrogens such as ICI 182,780 prevent the growth of estrogen sensitive tissue, the
contribution of other mechanisms cannot be ruled out as these compounds also block
metabolism and redox cycling of estrogen, and are free radical scavengers (Arteaga et al.,
2003). Even though the estrogenic potency of PCBs are weak compared to 17β-estradiol,
this study has reported significant fold differences in PCB-induced gene expression
compared to the natural hormone. These differences may be explained by redox signaling
pathways. Our previous studies have shown that physiological concentrations of estradiol
induce the formation of ROS involved in signaling cell proliferation and vascularization
(Felty, 2006;Felty and Porther, 2008). Coplanar PCBs like PCB126 bind with a high affinity
to the aryl hydrocarbon receptor (AhR) and induce AhR mediated gene expression of
cytochrome P450 1A1 (Hennig et al., 2002). This increase in CYP1A1 was implicated as a
mechanism for the oxidative stress and inflammatory response in PCB126 treated
endothelial cells reported by Hennig et al. Non-coplanar PCBs like PCB153 are not good
ligands for the AhR and their mechanisms of action are not completely understood.
Although these compounds have been reported to possess estrogenic activity, the observed
profile differences clearly show a different mechanism of vascular gene expression for each
chemical treatment. Estradiol-induced gene expression will be different based on nuclear ER
mediated transcription. PCB126 expression changes will differ from estradiol via AhR
mediated transcription. PCB153 does not bind with high affinity to either the nuclear ER or
AhR. Even though PCB153 is considered to be estrogenic; the changes in gene expression
cannot be explained by nuclear ER mediated signaling. There is evidence for PCB153
mediated activation of NADPH oxidase (Eum et al., 2009). Since NADPH oxidase is a
known source of cellular ROS; it is possible that redox sensitive signaling pathways are
responsible for the different gene changes observed in endothelial cells exposed to PCB153
when compared to PCB126 and estradiol treatment groups.
Estrogen produces both beneficial and adverse effects on cardiovascular health via
mechanisms that remain unclear. The present study provides the first gene expression
analysis comparing estrogenic chemicals PCB153 and PCB126 with the natural hormone
17β-estradiol in human vascular endothelial cells. Growing evidence implicates the
overproduction of ROS such as hydrogen peroxide (H2O2), superoxide anion (O2•−), and
peroxynitrite (ONOO−) in the development of CVD. Thus, identification of redox signaling
pathways that mediate vascularization may add to the knowledge base of how estrogenic
environmental chemicals influence the vascular wall. We believe that these gene profiles
may lead to insights into the pathophysiological mechanisms of vascular lesion formation
involved in PAH and provide a target pathway for therapeutic intervention.
Acknowledgments
This work was supported in part by a grant from NIH SC3GM084827 (Felty, Q.)
Reference List
The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA.
1970; 214(7):1303–1313. [PubMed: 4320008]
The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The
coronary Drug Project Research Group. JAMA. 1973; 226(6):652–657. [PubMed: 4356847]
ARTEAGA E, VILLASECA P, BIANCHI M, ROJAS A, MARSHALL G. Raloxifene is a better
antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in
vitro. Menopause. 2003; 10(2):142–146. [PubMed: 12627039]
BITMAN J, CECIL HC. Estrogenic activity of DDT analogs and polychlorinated biphenyls.
J.Agric.Food Chem. 1970; 18(6):1108–1112. [PubMed: 5483049]
Felty et al. Page 7
Life Sci. Author manuscript; available in PMC 2011 June 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
BOCCHINFUSO WP, HIVELY WP, COUSE JF, VARMUS HE, KORACH KS. A mouse mammary
tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice
lacking estrogen receptor-alpha. Cancer Res. 1999; 59(8):1869–1876. [PubMed: 10213494]
CAULIN-GLASER T, WATSON CA, PARDI R, BENDER JR. Effects of 17beta-estradiol on
cytokine-induced endothelial cell adhesion molecule expression. J.Clin.Invest. 1996; 98(1):36–42.
[PubMed: 8690801]
CHAMBLISS KL, YUHANNA IS, ANDERSON RG, MENDELSOHN ME, SHAUL PW. ERbeta has
nongenomic action in caveolae. Mol.Endocrinol. 2002; 16(5):938–946. [PubMed: 11981029]
CHOI W, EUM SY, LEE YW, HENNIG B, ROBERTSON LW, TOBOREK M. PCB 104-induced
proinflammatory reactions in human vascular endothelial cells: relationship to cancer metastasis and
atherogenesis. Toxicol.Sci. 2003; 75(1):47–56. [PubMed: 12805654]
CID MC, ESPARZA J, SCHNAPER HW, JUAN M, YAGUE J, GRANT DS, URBANO-MARQUEZ
A, HOFFMAN GS, KLEINMAN HK. Estradiol enhances endothelial cell interactions with
extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis.
1999; 3(3):271–280. [PubMed: 14517426]
CID MC, KLEINMAN HK, GRANT DS, SCHNAPER HW, FAUCI AS, HOFFMAN GS. Estradiol
enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an
increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1,
and vascular cell adhesion molecule type 1. J.Clin.Invest. 1994; 93(1):17–25. [PubMed: 7506711]
CID MC, SCHNAPER HW, KLEINMAN HK. Estrogens and the vascular endothelium.
Ann.N.Y.Acad.Sci. 2002; 966:143–157. [PubMed: 12114268]
COX RL, CRAWFORD ED. Estrogens in the treatment of prostate cancer. J.Urol. 1995; 154(6):1991–
1998. [PubMed: 7500443]
DAVEY JC, BODWELL JE, GOSSE JA, HAMILTON JW. Arsenic as an endocrine disruptor: effects
of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol.Sci.
2007; 98(1):75–86. [PubMed: 17283378]
DAVIES RJ, MORRELL NW. Molecular mechanisms of pulmonary arterial hypertension: role of
mutations in the bone morphogenetic protein type II receptor. Chest. 2008; 134(6):1271–1277.
[PubMed: 19059957]
DUMOND JW JR. SINGH KP, ROY D. Regulation of the growth of mouse Leydig cells by the
inactive stereoisomer, 17alpha-estradiol: Lack of correlation between the elevated expression of
ERalpha and difference in sensitivity to estradiol isomers. Oncol.Rep. 2001; 8(4):899–902.
[PubMed: 11410806]
EUM SY, ANDRAS I, HENNIG B, TOBOREK M. NADPH oxidase and lipid raft-associated redox
signaling are required for PCB153-induced upregulation of cell adhesion molecules in human
brain endothelial cells. Toxicol.Appl.Pharmacol. 2009; 240(2):299–305. [PubMed: 19632255]
EUM SY, LEE YW, HENNIG B, TOBOREK M. VEGF regulates PCB 104-mediated stimulation of
permeability and transmigration of breast cancer cells in human microvascular endothelial cells.
Exp.Cell Res. 2004; 296(2):231–244. [PubMed: 15149853]
FELTY Q. Estrogen-induced DNA synthesis in vascular endothelial cells is mediated by ROS
signaling. BMC.Cardiovasc.Disord. 2006; 6:16. [PubMed: 16608521]
FELTY Q, PORTHER N. Estrogen-induced redox sensitive Id3 signaling controls the growth of
vascular cells. Atherosclerosis. 2008; 198(1):12–21. [PubMed: 18281048]
GONCHAROV A, HAASE RF, SANTIAGO-RIVERA A, MORSE G, MCCAFFREY RJ, REJ R,
CARPENTER DO. High serum PCBs are associated with elevation of serum lipids and
cardiovascular disease in a Native American population. Environ Res. 2008; 106(2):226–239.
[PubMed: 18054906]
GUSTAVSSON P, HOGSTEDT C. A cohort study of Swedish capacitor manufacturing workers
exposed to polychlorinated biphenyls (PCBs). Am J.Ind.Med. 1997; 32(3):234–239. [PubMed:
9219652]
HAY A, TARREL J. Mortality of power workers exposed to phenoxy herbicides and polychlorinated
biphenyls in waste transformer oil. Ann.N.Y.Acad.Sci. 1997; 837:138–156. [PubMed: 9472337]
Felty et al. Page 8
Life Sci. Author manuscript; available in PMC 2011 June 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
HENNIG B, HAMMOCK BD, SLIM R, TOBOREK M, SARASWATHI V, ROBERTSON LW.
PCB-induced oxidative stress in endothelial cells: modulation by nutrients. Int.J.Hyg.Environ
Health. 2002; 205(1–2):95–102. [PubMed: 12018021]
HOWARD BV, HSIA J, OUYANG P, VAN VL, LINDSAY J, SILVERMAN A, ALDERMAN EL,
TRIPPUTI M, WATERS DD. Postmenopausal hormone therapy is associated with atherosclerosis
progression in women with abnormal glucose tolerance. Circulation. 2004; 110(2):201–206.
[PubMed: 15226212]
HYDUK A, CROFT JB, AYALA C, ZHENG K, ZHENG ZJ, MENSAH GA. Pulmonary hypertension
surveillance--United States, 1980–2002. MMWR Surveill Summ. 2005; 54(5):1–28. [PubMed:
16280974]
IREY NS, NORRIS HJ. Intimal vascular lesions associated with female reproductive steroids.
Arch.Pathol. 1973; 96(4):227–234. [PubMed: 4743889]
KIM-SCHULZE S, MCGOWAN KA, HUBCHAK SC, CID MC, MARTIN MB, KLEINMAN HK,
GREENE GL, SCHNAPER HW. Expression of an estrogen receptor by human coronary artery
and umbilical vein endothelial cells. Circulation. 1996; 94(6):1402–1407. [PubMed: 8822999]
KLEIGER RE, BOXER M, INGHAM RE, HARRISON DC. Pulmonary hypertension in patients using
oral contraceptives. A report of six cases. Chest. 1976; 69(2):143–147. [PubMed: 1248265]
LI X, ZHANG X, LEATHERS R, MAKINO A, HUANG C, PARSA P, MACIAS J, YUAN JX,
JAMIESON SW, THISTLETHWAITE PA. Notch3 signaling promotes the development of
pulmonary arterial hypertension. Nat.Med. 2009; 15(11):1289–1297. [PubMed: 19855400]
LIVAK KJ, SCHMITTGEN TD. Analysis of relative gene expression data using real-time quantitative
PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402–408. [PubMed: 11846609]
MEEK MD, FINCH GL. Diluted mainstream cigarette smoke condensates activate estrogen receptor
and aryl hydrocarbon receptor-mediated gene transcription. Environ.Res. 1999; 80(1):9–17.
[PubMed: 9931222]
NEWMAN JH, FANBURG BL, ARCHER SL, BADESCH DB, BARST RJ, GARCIA JG, KAO PN,
KNOWLES JA, LOYD JE, MCGOON MD, MORSE JH, NICHOLS WC, RABINOVITCH M,
RODMAN DM, STEVENS T, TUDER RM, VOELKEL NF, GAIL DB. Pulmonary arterial
hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of
Rare Diseases workshop. Circulation. 2004; 109(24):2947–2952. [PubMed: 15210611]
RAMOS, KSCEAD, JR.. Toxic Responses of the Heart and Vascular Systems. In: Klaassen, CD.,
editor. Casarett & Doull's Toxicology: The Basic Science of Poisons. McGraw-Hill; New York:
1996. p. 487-527.
ROSSOUW JE. Coronary heart disease in menopausal women: implications of primary and secondary
prevention trials of hormones. Maturitas. 2005; 51(1):51–63. [PubMed: 15883110]
SAKAO S, TATSUMI K, VOELKEL NF. Endothelial cells and pulmonary arterial hypertension:
apoptosis, proliferation, interaction and transdifferentiation. Respir.Res. 2009; 10:95. [PubMed:
19825167]
SELIMOVIC N, BERGH CH, ANDERSSON B, SAKINIENE E, CARLSTEN H, RUNDQVIST B.
Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension.
Eur.Respir.J. 2009; 34(3):662–668. [PubMed: 19324949]
SERGEEV AV, CARPENTER DO. Hospitalization rates for coronary heart disease in relation to
residence near areas contaminated with persistent organic pollutants and other pollutants. Environ
Health Perspect. 2005; 113(6):756–761. [PubMed: 15929900]
TAVOLARI S, BUCCI L, TOMASI V, GUARNIERI T. Selected polychlorobiphenyls congeners bind
to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating
angiogenesis. Toxicology. 2006; 218(1):67–74. [PubMed: 16293362]
TOKUNAGA S, KATAOKA K. A longitudinal analysis on the association of serum lipids and
lipoproteins concentrations with blood polychlorinated biphenyls level in chronic "Yusho"
patients. Fukuoka Igaku Zasshi. 2003; 94(5):110–117. [PubMed: 12872711]
VENETSANAKOS E, MIRZA A, FANTON C, ROMANOV SR, TLSTY T, MCMAHON M.
Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by
glioblastoma cells. Exp.Cell Res. 2002; 273(1):21–33. [PubMed: 11795943]
Felty et al. Page 9
Life Sci. Author manuscript; available in PMC 2011 June 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
WASSERMANN M, WASSERMANN D, CUCOS S, MILLER HJ. World PCBs map: storage and
effects in man and his biologic environment in the 1970s. Ann.N.Y.Acad.Sci. 1979; 320:69–124.
[PubMed: 110205]
YANG SH, LIU R, PEREZ EJ, WEN Y, STEVENS SM JR. VALENCIA T, BRUN-ZINKERNAGEL
AM, PROKAI L, WILL Y, DYKENS J, KOULEN P, SIMPKINS JW. Mitochondrial localization
of estrogen receptor beta. Proc.Natl.Acad.Sci.USA. 2004; 101(12):4130–4135. [PubMed:
15024130]
YOO C, COOPER GF. An evaluation of a system that recommends microarray experiments to
perform to discover gene-regulation pathways. Artif.Intell.Med. 2004; 31(2):169–182. [PubMed:
15219293]
Felty et al. Page 10
Life Sci. Author manuscript; available in PMC 2011 June 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Scatter plot report for RT2 Profiler PCR array for Human Angiogenesis analysis of cDNA
from RNA isolated from untreated HMVEC or HMVEC treated for 24h with (A) 17β-
estradiol 1ng/ml, (B) PCB126 100ng/ml, and (C) PCB153 100ng/ml. The figure depicts a
log transformation plot of the relative expression level of each gene between the estrogen
treated and untreated HMVEC. Changes in mRNA expression were calculated by the ΔΔCT
method. The figure is labeled with estrogen treatment on y-axis and untreated x-axis. The
red lines indicate a 3-fold change in gene expression.
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Fig. 2.
Hierarchical cluster of HMVEC gene expression changes in response to estrogen treatments.
Each row represents an individual gene, and each column represents three independent
experiments (n=3, estradiol, PCB126, PCB153). Up- (red) or Down- (green) regulated.
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Fig. 3.
A Bayesian Network representing a hypothetical gene-regulation pathway. This structure of
a hypothetical Bayesian Network contains five nodes. The probabilities associated with this
network structure are not shown. The network structure indicates that Gene1 can regulate
(influence) the expression level of Gene3, which in turn can regulate the expression level of
Gene5. The Markov condition gives the conditional independence relationships that are
specified by a Bayesian Network: A node is independent of its non-descendants (e.g., non-
effects) given its parents (i.e., its direct influences).
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Fig. 4.
Gene networks regulated by estrogen treatment. The node labeled “Experiment” in the
figure represents the experiment performed, i.e., control, estradiol, PCB126, or PCB153.
Other than the Experiment node, each node either represents a group of genes previously
mentioned or a single gene. The network identified that the following genes to have direct
influence of the Experiment node, i.e., the following genes are the Markov Blanket of
“Experiment” node: G1, VEGFA, CXCL6, HPSE, and TGFBR1.
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Table 1
Up/Down-Regulated Genes
Functional Groups Description Up/Down Regulation (Compared to control)
Adhesion Molecules
Estradiol PCB126 PCB153
ANGPTL3 Angiopoietin-like 3 0.05 −1.93 −5.27
BAI1 Brain-specific angiogenesis inhibitor 1 −3.32 −5.46 −10.45
CDH5 Cadherin 5, type 2 −1.20 −1.29 5.05
COL4A3 Collagen, type XVII, alpha 1 −1.74 0.03 1.58
COL4A3 Collagen, type IV, alpha 3 −2.35 −5.02 −7.46
ENG Endoglin 0.11 0.51 −0.46
IL8 Interleukin 8 −1.60 −2.60 6.07
ITGAV Integrin, alpha V 0.02 −1.20 4.12
ITGB3 Integrin beta 3 0.44 0.76 0.55
LAMA5 Laminin, alpha 5 −0.51 −1.77 −2.73
NRP1 Neuropilin 1 0.01 0.33 0.80
NRP2 Neuropilin 2 0.06 0.29 1.32
STAB1 Stabilin 1 −0.50 −2.47 1.43
THBS1 Thrombospondin 1 1.70 1.23 1.44
THBS2 Thrombospondon 2 −1.80 −3.30 −40.40
Cytokines & Chemokines
Estradiol PCB126 PCB153
CCL11 Chemokine (C-C motif) ligand 11 −2.18 −7.37 −8.28
CCL2 Chemokine (C-C motif) ligand 2 −1.14 −1.60 4.20
CXCL1 Chemokine (C-X-C motif) ligand 1 −0.14 −2.16 0.64
CXCL10 Chemokine (C-X-C motif) ligand 10 −1.14 −3.72 4.17
CXCL3 Chemokine (C-X-C motif) ligand 3 −1.66 −2.38 0.85
CXCL5 Chemokine (C-X-C motif) ligand 5 −1.43 −2.21 −1.47
CXCL6 Chemokine (C-X-C motif) ligand 6 0.02 −2.71 1.05
CXCL9 Chemokine (C-X-C motif) ligand 9 −1.58 −0.74 −1.29
IFNA1 Irterferon, alpha 1 −2.43 −3.68 −17.44
IFNB1 Irterferon, beta 1, fibroblast −1.53 −3.40 −0.55
IFNG Interferon, gamma −2.58 −4.87 −8.20
IL1B Interleukin 1, beta −2.42 −2.41 0.98
IL6 Interleukin 6 (interferon, beta 2) −1.76 −3.02 2.44
MDK Midkine −0.01 2.18 −1.15
TNF Tumor necrosis factor −2.04 −5.30 −0.85
Growth Factnrs & Receptors
Estradiol PCB126 PCB153
ANGPT1 Angiopoietin 1 −3.45 −5.49 −42.88
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Functional Groups Description Up/Down Regulation (Compared to control)
ANGPT2 Angiopoietin 2 1.40 1.32 0.08
ANPEP Alanyl(membrane) aminopeptidase −0.15 0.53 0.53
TYMP Tnymidine phosphorylase −1.53 −5.74 −2.95
S1PR1 Sphingosine-1-phosphate receptor 1 1.17 1.15 2.56
EFNA1 Ephrin-A1 −0.37 0.36 1.68
EFNA3 Ephrin-A3 −2.50 −3.14 −4.45
EFNB2 Ephrin-B2 −0.69 0.09 1.30
EGF Epidermal growth factor −2.15 −4.39 −16.62
EPHB4 EPH receptor B4 0.16 0.92 −1.78
EREG Epiregulin −0.21 −3.46 −1.79
FGF1 Fibroblast growth factor 1 (acidic) −2.54 −4.14 −10.13
FGF2 Fibroblast growth factor 2 (basic) 0.11 −1.61 0.34
FGFR3 Fibroblast growth factor receptor 3 −2.29 −4.53 −6.61
FIGF C-fos induced growth factor −0.15 −1.97 −2.28
FLT1 Fm5-related tyrosine kinase 1 −0.26 0.11 1.94
HGF Hepatocyte growth factor −2.25 −2.68 −2.30
IGF1 Insulin-like growth factor 1 −2.44 −4.56 −7.82
JAG1 Jagged 1 (Alagille syndrome) −0.94 −2.81 0.86
KDR Kinase insert domain receptor −0.25 −0.17 −1.65
PDGFA Platelet-derived growth factor alpha 0.06 0.00 3.41
PGF Placental growth factor −0.05 1.60 0.34
PLXDC1 Plexin domain containing 1 −1.86 −4.23 −5.34
TEK TEK tyrosine kinase, endothelial −0.52 0.00 3.95
TGFA Transforming growth factor, alpha −1.76 −4.80 −0.81
TGFB1 Transforming growth factor, beta 1 −0.35 0.45 −2.20
TGFB2 Transforming growth factor, beta 2 2.39 0.26 4.14
TGFBR1 Transforming growth factor, beta receptor 1 −1.39 −2.06 −1.15
VEGFA Vascular endothelial growth factor A 0.06 0.15 2.81
VEGFC Vascular endothelial growth factor A 0.06 0.15 4.45
Proteases, inhibitors, other matrix proteins
Estradio PCB126 PCB153
ANGPTL4 Angiopoietin-like 4 0.55 −1.38 2.70
LECT1 Leukocyte cell derived chemotaxin 1 −2.31 −3.65 −18.68
LEP Leptin −2.11 −4.14 −34.01
MMP2 Matrix metallopeptidase 2 −0.76 0.32 0 48
MMP9 Matrix metallopeptidase 9 −1.94 −6.80 −2.60
PECAM1 Platelet/endothelial cell adhesion molecule 1.40 0.31 0.84
PF4 Platelet factor 4 −1.83 −3.74 −6.94
PLAU Plasminogen activator, urokinase 0.22 0.21 −0.13
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Functional Groups Description Up/Down Regulation (Compared to control)
PLG Plasminogen −2.48 −3.53 −12.35
PROK2 Prokineticin 2 −2.45 −4.30 −50.87
SERPINF1 Serpin peptidase inhibitor, clade F −0.29 −1.78 −1.84
TIMP1 TIMP metallopeptidase inhibitor 1 −1.55 −1.82 0.65
TIMP2 TIMP metallopeptidase inhibitor 2 0.03 −0.10 1.63
TIMP3 TIMP metallopeptidase inhibitor 3 −2.73 −6.13 −15.82
TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 −1.01 −2.23 1.94
Transcription factors & Others
Estradiol PCB126 PCB153
AKT1 V-akt murine thymoma viral oncogene homolog 1 −0.64 0.45 −1.92
HAND2 Heart and neural crest derivatives expressed 2 −2.46 −7.73 −71.51
HIF1A Hypoxia inducible factor 1, alpha subunit 0.02 −0.23 1.69
HPSE Heperanase −0.28 −1.45 1.32
ID1 Inhibitor of DNA binding 1 0.21 −0.22 −0.50
ID3 Inhibitor of DNA binding 3 −1.30 −1.76 1.45
NOTCH4 Notch homolog 4 (Drosophila) −1.97 −2.44 2.59
PTGS1 Prostaglandin-endoperoxide synthase 1 1.11 1.75 −0.68
SPHK1 Sphingosine kinase 1 −0.56 −0.06 −0.19
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Table 2
Gene Groups Identified by Bayesian Network
Group Name Genes
G1 ANPEP, IL8, NRP2, PGF, TEK, TIMP2
G2 PLAU, HPRT1
G3 IL6, VEGFC, CXCL10
G4 FLT1, FGF2, PDGFA
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